Human leucocyte antigen-A2 increases risk of Alzheimer's disease but does not affect age of onset in a Scottish population

Neurosci Lett. 2000 Nov 10;294(1):37-40. doi: 10.1016/s0304-3940(00)01539-1.


The use of non-steroidal anti-inflammatory drugs has been associated with a reduced incidence of Alzheimer's disease (AD), suggesting that attenuation of the inflammatory response may be beneficial. Several, but not all, genetic association studies have shown human leucocyte antigen (HLA)-A2, a major histocompatibility complex class I antigen-binding transmembrane protein has an increased frequency in AD compared to controls, and in some reports is associated with a lowered age of onset. We further investigated the role of HLA-A2 in an independent sample of AD cases, including a large early onset cohort. The results of this current study and meta analysis of all studies available to date support previous evidence of an excess of HLA-A2 in AD, but found no evidence of a relationship with age of onset.

Publication types

  • Meta-Analysis
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Age Distribution
  • Age of Onset
  • Aged
  • Alleles
  • Alzheimer Disease / epidemiology*
  • Alzheimer Disease / genetics*
  • Apolipoprotein E4
  • Apolipoproteins E / genetics
  • Case-Control Studies
  • Cohort Studies
  • Female
  • Gene Frequency
  • HLA-A2 Antigen / genetics*
  • Humans
  • Logistic Models
  • Male
  • Middle Aged
  • Odds Ratio
  • Risk Assessment
  • Scotland / epidemiology
  • Sex Distribution


  • Apolipoprotein E4
  • Apolipoproteins E
  • HLA-A2 Antigen